Article Versions Notes

Lazaratos A-M, Dankner M, Hamouda A, Labidi S, Cohen V, Panasci L, Friedmann JE, Patenaude F, Ferrario C, Basik M, et al. The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre. Current Oncology. 2025; 32(1):1. https://doi.org/10.3390/curroncol32010001

Lazaratos, Anna-Maria, Matthew Dankner, Aalya Hamouda, Soumaya Labidi, Victor Cohen, Lawrence Panasci, Jennifer E. Friedmann, François Patenaude, Cristiano Ferrario, Mark Basik, and et al. 2025. "The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre" Current Oncology 32, no. 1: 1. https://doi.org/10.3390/curroncol32010001

Lazaratos, A.-M., Dankner, M., Hamouda, A., Labidi, S., Cohen, V., Panasci, L., Friedmann, J. E., Patenaude, F., Ferrario, C., Basik, M., Rose, A. A. N., & Fallah, P. (2025). The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre. Current Oncology, 32(1), 1. https://doi.org/10.3390/curroncol32010001